$1.16 Billion is the total value of Redmile Group, LLC's 50 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AKAOQ | Exit | ACHAOGEN INC | $0 | – | -32,300 | -100.0% | -0.01% | – |
DXCM | Exit | DEXCOM INC | $0 | – | -2,460 | -100.0% | -0.02% | – |
BIIB | Exit | BIOGEN INC | $0 | – | -677 | -100.0% | -0.02% | – |
HUM | Exit | HUMANA INC | $0 | – | -1,390 | -100.0% | -0.02% | – |
FBT | Exit | FIRST TR EXCHANGE TRADED FDny arca biotech | $0 | – | -3,090 | -100.0% | -0.02% | – |
BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -27,539 | -100.0% | -0.06% | – |
ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -336,759 | -100.0% | -0.41% | – |
ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -45,410 | -100.0% | -0.44% | – |
IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -408,462 | -100.0% | -0.52% | – |
AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -288,356 | -100.0% | -0.75% | – |
PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -916,927 | -100.0% | -1.66% | – |
OPHT | Exit | OPHTHOTECH CORP | $0 | – | -505,154 | -100.0% | -1.85% | – |
SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -640,400 | -100.0% | -3.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
INVITAE CORP | 32 | Q3 2023 | 2.7% |
REGENXBIO INC | 28 | Q3 2023 | 3.8% |
CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
4 | 2024-05-10 |
4 | 2024-04-01 |
4 | 2024-04-01 |
4 | 2024-03-25 |
SC 13D/A | 2024-03-25 |
4 | 2024-03-19 |
4 | 2024-03-14 |
4 | 2024-03-13 |
SC 13D/A | 2024-03-13 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.